Program
erfonrilimab
Also written as “KN046”, “GT90001+KN046” and “KN046 (PD-L1/CTLA4 BsAb)”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Colorectal Neoplasms · Thymoma · Lymphoma · Triple Negative Breast Neoplasms, led by 4 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Alphamab Oncology | 111 open or running | phase 3since Jul 13, 2020 | May 8, 2018 | none ahead |
| Suzhou Kintor Pharmaceutical | 11 open or running | phase 2since Jul 5, 2021 | Jul 5, 2021 | none ahead |
| Suzhou Zelgen Biopharmaceuticals | 10 open or running | phase 2since Oct 29, 2020 | Oct 29, 2020 | none ahead |
| Zhejiang Raygene Pharmaceuticals | 10 open or running | phase 2since Feb 13, 2025 | Feb 13, 2025 | none ahead |
Also a collaborator on its studies: Sunshine Lake Pharma.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 8, 2018First study: phase 1 study in Advanced Solid TumorsNew to Alphamab OncologyAlphamab Oncology · NCT03529526 · 21 enrolled · Australia
- Oct 31, 2018Phase 1 study in LymphomaAlphamab Oncology · NCT03733951 · 139 enrolled · China
- Feb 1, 2019Phase 2 study in Carcinoma, Non-Small-Cell LungAlphamab Oncology · NCT03838848 · 120 enrolled · China
- Mar 7, 20192 phase 2 studiesAlphamab Oncology · NCT03872791, NCT03925870
- Jul 7, 2020Phase 2 study in ThymomaAlphamab Oncology · NCT04469725 · 95 enrolled · China
- Jul 13, 2020Phase 3 study in Squamous Non-small-cell Lung CancerAlphamab Oncology · NCT04474119 · 482 enrolled · China
- Oct 19, 2020Phase 2 study in Advanced HCCAlphamab Oncology · NCT04601610 · 6 enrolled · China
- Oct 29, 2020Suzhou Zelgen Biopharmaceuticals's first study: phase 2 study in Advanced Gastrointestinal TumorsNew to Suzhou Zelgen BiopharmaceuticalsSuzhou Zelgen Biopharmaceuticals · NCT04612712 · 15 enrolled · China
- Jul 5, 2021Suzhou Kintor Pharmaceutical's first study: phase 2 study in Solid TumorNew to Suzhou Kintor PharmaceuticalSuzhou Kintor Pharmaceutical · NCT04984668 · 216 planned · Taiwan
- Jul 16, 2021Phase 3 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT05001724 · 16 enrolled · China
- Nov 26, 2021Phase 3 study in Advanced Pancreatic Ductal AdenocarcinomaAlphamab Oncology · NCT05149326 · 408 enrolled · China
- Jun 12, 2022Phase 2 study in Advanced Non-small Cell Lung CancerAlphamab Oncology · NCT05420220 · 95 enrolled · China
- Feb 13, 2025Zhejiang Raygene Pharmaceuticals's first study: phase 2 study in Colorectal NeoplasmsNew to Zhejiang Raygene PharmaceuticalsZhejiang Raygene Pharmaceuticals · NCT06834399 · 42 enrolled · China
TargetBeta
“A bispecific monoclonal antibody directed against both the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), ”NCIt, by rule
“Cytotoxic T-lymphocyte protein 4 inhibitor; Programmed cell death 1 ligand 1 inhibitor”ChEMBL 37, by rule
Studies
All 14 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06834399Colorectal Neoplasms · China | 2 | Terminated | Zhejiang Raygene Pharmaceuticals | Dec 17, 2024 | 42 |
| NCT05420220Advanced Non-small Cell Lung Cancer · China | 2 | Completed | Alphamab Oncology | Dec 31, 2024 | 95 |
| NCT05149326Advanced Pancreatic Ductal Adenocarcinoma · China | 3 | Active, not recruiting | Alphamab Oncology | Apr 30, 2024 | 408 |
| NCT05001724Advanced Non-small Cell Lung Cancer · China | 3 | Terminated | Alphamab Oncology | Feb 13, 2023 | 16 |
| NCT04984668Solid Tumor · Taiwan | 2 | Recruiting | Suzhou Kintor Pharmaceutical | Apr 2025 | 216 |
| NCT04612712Advanced Gastrointestinal Tumors · China | 2 | Terminated | Suzhou Zelgen Biopharmaceuticals | Jun 30, 2022 | 15 |
| NCT04601610Advanced HCC · China | 2 | Terminated | Alphamab Oncology | May 30, 2022 | 6 |
| NCT04474119Squamous Non-small-cell Lung Cancer · China | 3 | UNKNOWN | Alphamab Oncology | Aug 30, 2022 | 482 |
| NCT04469725Thymoma · China | 2 | Terminated | Alphamab Oncology | Jul 7, 2023 | 95 |
| NCT03925870Esophageal Squamous Cell Carcinoma · China | 2 | Completed | Alphamab Oncology | Aug 26, 2021 | 45 |
| NCT03872791Triple Negative Breast Neoplasms · China | 2 | Completed | Alphamab Oncology | Aug 16, 2022 | 52 |
| NCT03838848Carcinoma, Non-Small-Cell Lung · China | 2 | Terminated | Alphamab Oncology | Jul 30, 2022 | 120 |
| NCT03733951Lymphoma · China | 1 | Completed | Alphamab Oncology | Jan 3, 2023 | 139 |
| NCT03529526Advanced Solid Tumors · Australia | 1 | UNKNOWN | Alphamab Oncology | Oct 30, 2019 | 21 |
How it is read
Names in the registry
- “KN046”, 11 entries
- “GT90001+KN046”, 4 entries
- “KN046 (PD-L1/CTLA4 BsAb)”, 2 entries
- “KN046 (Recombinant Humanized PD-L1/CTLA-4 Bispecific Single Domain Antibody Fc Fusion Protein Injection)”, 1 entry
- “KN046 Injection”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 4 studies
- Colorectal Neoplasms, 1 study
- Thymoma, 1 study
- Lymphoma, 1 study
- Triple Negative Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.